Skip to main content
OpenTrials
Completed

NCT Number: NCT00241579

Analgesic Efficacy of Smoked Cannabis

The purpose of this study is to determine whether or not inhaled marijuana displays any pain-relieving properties on experimentally-induced pain.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

UC San Diego Medical Center

San Diego, California, 92093, United States

About this study

It is important to evaluate the effects of the cannabinoids on facilitated pain as conditions of hyperalgesia more closely approximates the clinical situation. There are limited clinical studies on the effect of the cannabinoids on facilitated pain states. Noyes et al evaluated the analgesic effects of Delta-9-THC in 34 cancer patients with pain. They concluded that 20mg of oral Delta-9-THC was similar to 120mg of codeine (Noyes et al, 1975). Jain et al concluded that 1.5-3mg of intramuscular Levonantradol resulted in significant pain relief as compared to placebo in 56 patients with acute postoperative pain (Jain et al, 1981).

Comparison(s): Three different doses of smoked cannabis will be compared to placebo for the reduction of experimentally induced pain.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-90
  • Male or Female
  • Subject smoked cannabis within the last six months

Exclusion criteria

  • Active opportunistic infections or opportunistic malignancies requiring acute treatment
  • Active substance abuse (alcohol or injection drug)
  • Pulmonary complications (e.g., tuberculosis, asthma)
  • Current use of cannabis (e.g., within 30 days of randomization)
  • Pregnancy as ascertained by a self-report and a mandatory commercial pregnancy test before any cannabis or placebo consumption condition
  • Personal or familial history of psychiatric disorder

Treatment and study plan

Smoked cannabis

Drug

Primary outcomes

  1. Score on a Visual Analog Scale (VAS) of pain severity

  2. McGill Pain Questionnaire (MPQ) Short Form

  3. Neurosensory testing of: 1) warm and cold sensation, 2) warm and cold pain, 3) touch, and 4) mechanical pain. Testing administered using a Thermal Sensory Analyzer, von Frey hair filaments, and a pinch algometer, respectively.

Secondary outcomes

  1. Trail Making Test (TMT) as a measure of psychomotor speed.

  2. Paced Auditory Serial Attention Test (PASAT) as a measure of speed of information processing.

Sponsors and collaborators

Lead sponsor

Center for Medicinal Cannabis Research

Other

Registry information

Important dates

Study start
2002
Study completion
2004
First posted
Oct 19, 2005
Registry last updated
Jun 23, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.